Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ENDRA Life Sciences (NDRA) EPS (Basic) (2016 - 2025)

ENDRA Life Sciences has reported EPS (Basic) over the past 6 years, most recently at -$5.35 for Q4 2021.

  • Quarterly EPS (Basic) fell 2331.82% to -$5.35 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$5.55 through Dec 2021, down 545.35% year-over-year, with the annual reading at -$8.93 for FY2025, 84.32% up from the prior year.
  • EPS (Basic) was -$5.35 for Q4 2021 at ENDRA Life Sciences, down from -$0.06 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$0.06 in Q1 2021 and troughed at -$5.35 in Q4 2021.
  • The 5-year median for EPS (Basic) is -$0.34 (2019), against an average of -$0.67.
  • Year-over-year, EPS (Basic) surged 82.96% in 2017 and then crashed 2331.82% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at -$0.65 in 2017, then soared by 56.92% to -$0.28 in 2018, then plummeted by 328.57% to -$1.2 in 2019, then soared by 81.67% to -$0.22 in 2020, then crashed by 2331.82% to -$5.35 in 2021.
  • Per Business Quant, the three most recent readings for NDRA's EPS (Basic) are -$5.35 (Q4 2021), -$0.06 (Q3 2021), and -$0.08 (Q2 2021).